Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | VNN1 | O95497 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14526650 | 0.84 | HRH3 (0.45) | HRH3VNN1POLBSIGMAR1 | |
| SCHEMBL14453887 | 0.81 | HRH3 (0.39) | HRH3TLR9TLR8TLR7POLB | |
| SCHEMBL23367198 | 0.80 | TP53 (0.38) | HRH3PHGDHMGLLPOLB | |
| SCHEMBL12250826 | 0.79 | MEN1 (0.40) | HRH3VNN1POLBSIGMAR1 | |
| SCHEMBL1083799 | 0.79 | MEN1 (0.40) | HRH3VNN1POLBSIGMAR1 | |
| SCHEMBL12250827 | 0.79 | MEN1 (0.40) | HRH3VNN1POLBSIGMAR1 | |
| SCHEMBL8257116 | 0.79 | TLR9 (0.35) | HRH3TLR9TLR8TLR7POLB | |
| SCHEMBL21210800 | 0.79 | TLR9 (0.35) | HRH3TLR9TLR8TLR7POLB | |
| SCHEMBL19699825 | 0.79 | TLR9 (0.35) | HRH3TLR9TLR8TLR7POLB | |
| SCHEMBL8255509 | 0.78 | MEN1 (0.35) | HRH3TLR9TLR8TLR7POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256186-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171614-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | HRH3 789/4885PHGDH 3771/4885MGLL 1279/4885 |
| US-20050085506-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | HRH3 278/4885PHGDH 3479/4885MGLL 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.